Good patent protection policy is key to successful transfer of technology, ASEBIO meeting told

Speaking at BioSpain 2010, in Pamplona, Spain, organized by the Spanish Association of Biocompanies (ASEBIO), Conny Bogentoft, chief scientific officer at Sweden’s Karolinska Development AB, stressed the need to “build bridges between the academic world and the pharmaceutical industry.”

“It is increasingly difficult to receive financing and the financial crisis is weakening investment in R&D and investment (R&D+i)”, said Ms Bogentoft, who described the model of the unit she runs, focused mainly on “building bridges between the academic world and the pharmaceutical industry.” Karolinska Development AB has six projects in Phase II, six in Phase I and over 20 potential first-in-class components. In this context, the expert pointed out the need for a good patent protection policy.

“For a company it is important to know what universities and public institutions are doing regarding new technologies,” she stated